Nature Medicine publishes peptide-relevant clinical and translational research that often anchors major prescribing shifts on this site. The journal sits between the basic-science weight of Nature Communications and the clinical-trial-focused JAMA and NEJM coverage.
Representative pieces covered: GLP-1 cardiometabolic outcomes data, peptide vaccine long-term survival readouts (autogene cevumeran and similar), and clinical-translational mechanism work on peptide drug responsiveness.
Use this tag to scan the Nature Medicine coverage. For broader Nature family work, see #nature-communications.
Nature Medicine published Structure's Phase 2b ACCESS trial of aleniglipron, the once-daily oral small-molecule GLP-1, on June 5, with lead author Julio Rosenstock presenting the full data in a 12:45 p.m. CT oral session at ADA 2026 the same afternoon. The 44-week ACCESS II readout reached up to 16.3% placebo-adjusted weight loss, the strongest oral GLP-1 number outside Lilly's, and Structure plans to start Phase 3 in Q3 2026 with a 2.5 mg starting dose after end-of-Phase-2 FDA alignment.
The European Association for the Study of Obesity published an updated pharmacological framework in Nature Medicine, presented at ECO 2026 in Istanbul on Thursday May 14. Semaglutide and tirzepatide are recommended as first-line treatment for obesity across most complications. Tirzepatide is preferred for obstructive sleep apnea and MASH; semaglutide is preferred for knee osteoarthritis and established cardiovascular disease — and is the only agent with current evidence supporting MASH-fibrosis improvement. The framework integrated evidence through November 21, 2025 from 62 randomized controlled trials. The algorithm uses obesity-related complication presence as the primary treatment-selection factor and provides the first major obesity-society guideline to formally privilege incretin-based therapy across the indication mix.
Eli Lilly published SURMOUNT-MAINTAIN in The Lancet and ATTAIN-MAINTAIN in Nature Medicine on May 12, with concurrent presentation at ECO 2026 in Istanbul. SURMOUNT-MAINTAIN tested lower-dose Zepbound (tirzepatide 5 mg) vs maximum tolerated dose: at week 112, MTD preserved all weight loss while the 5 mg arm lost only 5.6 kg additional. ATTAIN-MAINTAIN tested Foundayo (orforglipron) as a switch from injectable GLP-1s in SURMOUNT-5 participants: orforglipron preserved 79.3% of injectable-phase weight loss vs 37.6% on placebo at week 52; Wegovy MTD switchers regained only 0.9 kg, Zepbound MTD switchers regained 5.0 kg. The dual readout reframes the maintenance-versus-discontinuation conversation: dose-tapering and oral-switching strategies now have Phase 3 evidence behind them, validating the long-term-treatment chronic-disease framing.
Final phase 1 AMPLIFY-201 results published in Nature Medicine report that ELI-002 2P — a lymph node-targeted vaccine combining amphiphile-modified mutant KRAS G12D/G12R peptides with CpG-7909 adjuvant — produced durable responses in 25 patients with minimal residual mKRAS disease (20 pancreatic, 5 colorectal). At 19.7 months median follow-up, robust T-cell responders achieved median relapse-free survival not reached vs. 3.02 months in non-responders (HR 0.12, p=0.0002); 71% of evaluable patients generated both CD4+ and CD8+ T cells, and antigen spreading was observed in 67%. Phase 2 enrollment of the next-generation 7-peptide formulation ELI-002 7P is complete, with results expected in 2026.
The ELAD trial — a multicenter, randomized, double-blind, placebo-controlled Phase 2b study of liraglutide in 204 mild-to-moderate Alzheimer's disease participants — published in Nature Medicine (online December 2025) continues to drive clinical-research discussions about GLP-1s in neurodegeneration. Coming after the Phase 3 EVOKE trials' negative cognition results, ELAD's intermediate-stage findings are being parsed for endpoints, mechanisms, and biomarker patterns that may guide future trial design in this contested indication.
A comprehensive review by D.J. Drucker in Nature Medicine outlines GLP-1 medicines expanding beyond diabetes and obesity into cardiovascular disease, neurodegenerative disorders, substance use, metabolic liver disease, arthritis, type 1 diabetes, and inflammatory bowel disease. New multi-agonist molecules with optimized pharmacokinetics are producing greater weight loss.